- Home
- ORGO vs HURA Comparison
ORGO vs HURA Comparison
Compare ORGO & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ORGO | HURA |
|---|---|---|
| Founded | 1985 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 166.0M | 160.5M |
| IPO Year | 2016 | 2010 |
Fundamental Metrics
Financial Performance| Metric | ORGO | HURA |
|---|---|---|
| Price | $1.03 | $1.97 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 4 |
| Target Price | $2.00 | ★ $8.04 |
| AVG Volume (30 Days) | ★ 750.4K | 230.8K |
| Earning Date | 11-05-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1600.00 | 47.93 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $564,169,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $37.55 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 17.04 | N/A |
| 52 Week Low | $0.93 | $0.41 |
| 52 Week High | $7.08 | $3.43 |
Technical Indicators
Market Signals| Indicator | ORGO | HURA |
|---|---|---|
| Relative Strength Index (RSI) | 26.71 | 50.91 |
| Support Level | N/A | $1.83 |
| Resistance Level | $2.57 | $2.22 |
| Average True Range (ATR) | 0.08 | 0.13 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 23.06 | 53.06 |
Price Performance
Historical ComparisonAbout ORGO Organogenesis Holdings Inc.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.
About HURA TuHURA Biosciences Inc.
TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company operates in one reportable segment, which includes all activities related to advancing therapies for cancer treatment.